2026– date –
-
Bloom X³ Founder & CEO Hiro Kimura Participated in Coolwater Capital’s Investor Summit and Strengthened US Engagement in San Francisco
Bloom X³ Founder & CEO Hiro Kimura participated in Coolwater Capital's Investor Summit in San Francisco, strengthening US engagement and confirming strong international interest in the firm's life science investment strategy and the 1102 incubation project. -
Research Collaboration with Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Enters Phase 2 — The 1102 Program Toward Aging, Rejuvenation, and Regenerative Medicine
Bloom X³ advances its research collaboration with Kansai BNCT Medical Center to Phase 2. The 1102 Program looks beyond intractable cancers, toward aging, rejuvenation, and regenerative medicine. -
Bloom X³ News：Congratulations to Dr. Joe Bolen and Orna Therapeutics on the Acquisition by Eli Lilly
Bloom X³ Inc. extends its sincere congratulations to Dr. Joe Bolen, Advisor to Bloom X³ and Chief Executive Officer of Orna Therapeutics, and to the entire Orna team on the announced acquisition by Eli Lilly and Company. According to the... -
Meeting with Nobel Laureate Prof. Shinya Yamanaka
Bloom X³ Inc. (Founder & CEO: Hiromichi Kimura) recently met with Nobel Laureate Prof. Shinya Yamanaka at Gladstone Institutes (a UCSF-affiliated research institute) in California, USA. Prof. Yamanaka is Director Emeritus of the Cent... -
Invited Talk at ASDRP: “Research vs. Business—How to Navigate Career Inflection Points”
Our CEO (Hiro Kimura, Ph.D., R.Ph.) was invited to ASDRP’s Guest Speaker Series and delivered a lecture for high school students in the San Francisco Bay Area.*ASDRP (Aspiring Scholars Directed Research Program): a nonprofit, private res... -
Why Human Judgment Still Matters in AI Drug Discovery: Reproducibility, Credibility, and the Invisible Rules of Scientific Trust
Introduction: AI Is Not a Shortcut to Truth AI is transforming how we discover drugs. It accelerates structural predictions, target discovery, and literature mining. But as its use grows, so does a silent risk: misplaced trust in the cor...
1